Back to top
more

Regeneron Pharmaceuticals, Inc. (REGN)

(Real Time Quote from BATS)

$301.00 USD

301.00
158,838

-2.82 (-0.93%)

Updated Oct 16, 2019 11:31 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | C Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for REGN

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Regeneron Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 2,810 1,410 1,039 1,045 900
Receivables 2,243 1,974 1,612 1,468 1,017
Notes Receivable 0 0 0 0 0
Inventories 1,151 726 399 239 129
Other Current Assets 243 225 131 164 121
Total Current Assets 6,448 4,335 3,180 2,915 2,167
Net Property & Equipment 2,576 2,359 2,083 1,594 974
Investments & Advances 1,755 1,486 864 632 460
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 829 506 825 462 267
Intangibles 0 0 0 0 0
Deposits & Other Assets 127 78 20 6 3
Total Assets 11,735 8,764 6,973 5,609 3,872
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 0 0 0 0 0
Accounts Payable 218 815 879 644 484
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 127 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1,225 320 235 167 170
Total Current Liabilities 1,443 1,135 1,242 811 655
Mortgages 0 0 0 0 0
Deferred Taxes/Income 464 629 831 665 176
Convertible Debt 0 0 0 0 147
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 709 703 352 363 311
Other Non-Current Liabilities 362 152 100 116 41
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,977 2,620 2,524 1,954 1,330
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 3,912 3,513 3,030 3,100 2,404
Retained Earnings 5,254 2,947 1,748 853 255
Other Equity -12 1 -13 9 52
Treasury Stock 396 316 316 306 170
Total Shareholder's Equity 8,757 6,144 4,449 3,655 2,542
Total Liabilities & Shareholder's Equity 11,735 8,764 6,973 5,609 3,872
Total Common Equity 8,757 6,144 4,449 3,655 2,542
Shares Outstanding 109.00 107.60 106.00 104.60 102.40
Book Value Per Share 80.34 57.10 41.97 34.94 24.83

Fiscal Year End for Regeneron Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Assets          
Cash & Equivalents NA 2,670 3,232 2,810 2,192
Receivables NA 2,456 2,305 2,243 2,203
Notes Receivable NA 0 0 0 0
Inventories NA 1,317 1,209 1,151 1,040
Other Current Assets NA 208 182 243 285
Total Current Assets NA 6,651 6,929 6,448 5,720
Net Property & Equipment NA 2,677 2,613 2,576 2,524
Investments & Advances NA 2,885 2,340 1,755 1,874
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 822 829 829 563
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 140 144 127 125
Total Assets NA 13,174 12,855 11,735 10,806
Liabilities & Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Notes Payable NA 0 0 0 0
Accounts Payable NA 244 240 218 172
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1,469 1,272 1,225 1,245
Total Current Liabilities NA 1,713 1,511 1,443 1,417
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 725 813 464 619
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 711 710 709 707
Other Non-Current Liabilities NA 376 362 194
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 3,418 3,410 2,977 2,937
Shareholders Equity 9/30/2019 6/30/2019 3/31/2019 12/31/2018 9/30/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 4,264 4,161 3,912 3,841
Retained Earnings NA 5,918 5,725 5,254 4,434
Other Equity NA 16 3 -12 -11
Treasury Stock NA 442 444 396 396
Total Shareholder's Equity NA 9,756 9,445 8,757 7,868
Total Liabilities & Shareholder's Equity NA 13,174 12,855 11,735 10,806
Total Common Equity 0 9,756 9,445 8,757 7,868
Shares Outstanding 109.80 109.70 109.20 109.00 108.20
Book Value Per Share 0.00 88.93 86.49 80.34 72.72